首页> 美国卫生研究院文献>ACS Chemical Neuroscience >ML297 (VU0456810) the First Potent and SelectiveActivator of the GIRK Potassium Channel Displays Antiepileptic Propertiesin Mice
【2h】

ML297 (VU0456810) the First Potent and SelectiveActivator of the GIRK Potassium Channel Displays Antiepileptic Propertiesin Mice

机译:ML297(VU0456810)第一个有效的和选择性的GIRK钾离子通道的激活剂显示抗癫痫特性在老鼠

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The G-protein activated, inward-rectifying potassium (K+) channels, “GIRKs”, are a family of ion channels (Kir3.1-Kir3.4) that has been the focus of intense research interest for nearly two decades. GIRKs are comprised of various homo- and heterotetrameric combinations of four different subunits. These subunits are expressed in different combinations in a variety of regions throughout the central nervous system and in the periphery. The body of GIRK research implicates GIRK in processes as diverse as controlling heart rhythm, to effects on reward/addiction, to modulation of response to analgesics. Despite years of GIRK research, very few tools exist to selectively modulate GIRK channels’ activity and until now no tools existed that potently and selectively activated GIRKs. Here we report the development and characterization of the first truly potent, effective, and selective GIRK activator, ML297 (VU0456810). We further demonstrate that ML297 is active in two in vivo models of epilepsy, a disease where up to 40% of patients remain with symptoms refractory to present treatments. The development of ML297 representsa truly significant advancement in our ability to selectively probeGIRK’s role in physiology as well as providing the first toolfor beginning to understand GIRK’s potential as a target fora diversity of therapeutic indications.
机译:G蛋白激活的内向整流钾(K + )通道“ GIRKs”是离子通道家族(Kir3.1-Kir3.4),一直是深入研究的重点兴趣近二十年。 GIRK由四个不同亚基的各种同四聚体和异四聚体组合组成。这些亚基在整个中枢神经系统和周围区域的不同区域以不同的组合表达。 GIRK的研究机构将GIRK牵涉到各种过程中,例如控制心律,影响奖励/成瘾,调节对镇痛药的反应。尽管GIRK进行了多年的研究,但很少有工具可以选择性地调节GIRK渠道的活动,而到现在为止,还没有工具能够有效地和选择性地激活GIRK。在这里,我们报告了第一个真正有效,有效和选择性的GIRK激活剂ML297(VU0456810)的开发和表征。我们进一步证明,ML297在两种癫痫症的体内模型中均具有活性,该疾病中高达40%的患者仍具有目前治疗难以治愈的症状。 ML297的发展代表我们选择性探测能力的真正重大进步GIRK在生理学中的作用以及提供的第一个工具开始了解GIRK作为目标的潜力多种治疗适应症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号